{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:21Z","timestamp":1761901461504,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.msard.2019.101382","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T02:19:18Z","timestamp":1567477158000},"page":"101382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-012X","authenticated-orcid":false,"given":"Johannis A.","family":"van Rossum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zo\u00e9 L.E.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit I.","family":"Lissenberg-Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.101382_bib0001","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101382_bib0002","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.msard.2016.05.020","article-title":"Erythroblastaemia in natalizumab-treated patients with multiple sclerosis","volume":"8","author":"La Gioia","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.101382_bib0003","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1177\/1352458514521307","article-title":"The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis","volume":"20","author":"Robier","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101382_bib0004","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1212\/NXI.0000000000000123","article-title":"Hematologic modifications in natalizumab-treated multiple sclerosis patients: an 18-month longitudinal study","volume":"2","author":"Bridel","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.101382_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.msard.2019.101382_bib0006","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.blre.2017.09.002","article-title":"Erythroleukemia-historical perspectives and recent advances in diagnosis and management","volume":"32","author":"Boddu","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.msard.2019.101382_bib0007","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2019.101382_bib0008","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.wneu.2017.09.131","article-title":"Natalizumab-Associated primary central nervous system lymphoma","volume":"109","author":"Nixon","year":"2018","journal-title":"World Neurosurg."},{"key":"10.1016\/j.msard.2019.101382_bib0009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.wneu.2018.01.159","article-title":"Letter to the editor regarding \u201cNatalizumab-Associated primary central nervous system lymphoma\u201d","volume":"115","author":"Sartori","year":"2018","journal-title":"World Neurosurg."},{"key":"10.1016\/j.msard.2019.101382_bib0010","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.101382_bib0011","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2019.101382_bib0012","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","volume":"24","author":"van Kempen","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101382_bib0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.msard.2019.101382_bib0014","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2141.2010.08366.x","article-title":"A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty","volume":"151","author":"Zini","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.msard.2019.101382_bib0015","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1212\/NXI.0000000000000483","article-title":"Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod","volume":"5","author":"de Jong","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.101382_bib0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.msard.2019.01.041","article-title":"Erythroblast appearance associated with natalizumab","volume":"29","author":"Kobayashi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.101382_bib0017","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14712590903055011","article-title":"The role of natalizumab in hematopoietic stem cell mobilization","volume":"9","author":"Neumann","year":"2009","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819303591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819303591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:41Z","timestamp":1761900401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819303591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":17,"alternative-id":["S2211034819303591"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101382","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101382"}}